Trucco Massimo, Giannoukakis Nick
Children's Hospital of Pittsburgh, Diabetes Institute, Pittsburgh, PA 15213, USA.
Expert Opin Biol Ther. 2007 Jul;7(7):951-63. doi: 10.1517/14712598.7.7.951.
Herein, the authors provide an overview of where dendritic cells lie in the immunopathology of autoimmune Type 1 diabetes mellitus and how dendritic cell-based therapy may be usefully translated to treat and reverse the disease. The immunopathology of Type 1 diabetes mellitus offers a number of windows at which immunotherapy can be applied to delay, stop and even reverse the autoimmune processes, especially in light of the recent antibody-based accomplishment of improvement in residual beta-cell mass function. As in almost all cell-specific inflammatory processes, dendritic cells are central regulators of diabetes onset and progression. This realisation, along with accumulating data confirming a role for dendritic cells in maintaining and inducing tolerance in multiple therapeutic settings, has prompted a line of investigation to identify the most effective embodiments of dendritic cells for diabetes immunotherapy.
在此，作者概述了树突状细胞在自身免疫性1型糖尿病免疫病理学中的位置，以及基于树突状细胞的疗法如何有效地转化用于治疗和逆转该疾病。1型糖尿病的免疫病理学提供了多个窗口，可在这些窗口应用免疫疗法来延迟、阻止甚至逆转自身免疫过程，特别是鉴于最近基于抗体在改善残余β细胞团功能方面取得的成果。与几乎所有细胞特异性炎症过程一样，树突状细胞是糖尿病发病和进展的核心调节因子。这一认识，以及越来越多的数据证实树突状细胞在多种治疗环境中维持和诱导耐受性方面的作用，促使了一系列研究，以确定用于糖尿病免疫治疗的树突状细胞的最有效形式。
